William Blair Issues Positive Outlook for NMRA Earnings

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Neumora Therapeutics to ($0.28) per share, an improvement from the prior estimate of ($0.30).
• Neumora Therapeutics beat earnings expectations for their latest quarter, reporting ($0.33) EPS compared to the consensus estimate of ($0.38).
• The current consensus target price for Neumora Therapeutics stands at $7.14, with a mixed rating from analysts, including one sell, five holds, and three buy ratings.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Analysts at William Blair boosted their Q3 2025 earnings estimates for shares of Neumora Therapeutics in a report issued on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will earn ($0.28) per share for the quarter, up from their previous estimate of ($0.30). The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.32) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.91) EPS and FY2028 earnings at ($0.47) EPS.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05.

NMRA has been the subject of a number of other research reports. Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Mizuho increased their price target on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, Neumora Therapeutics currently has an average rating of "Hold" and a consensus target price of $7.14.

Neumora Therapeutics Stock Down 11.5%

NMRA stock opened at $1.46 on Monday. The company has a market cap of $236.15 million, a price-to-earnings ratio of -0.93 and a beta of 2.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The company has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.18.

Hedge Funds Weigh In On Neumora Therapeutics

A number of large investors have recently made changes to their positions in the stock. CWM LLC increased its holdings in Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company's stock valued at $26,000 after acquiring an additional 10,537 shares in the last quarter. PEAK6 LLC purchased a new position in Neumora Therapeutics during the 4th quarter valued at about $117,000. Wells Fargo & Company MN increased its holdings in Neumora Therapeutics by 23.0% during the 4th quarter. Wells Fargo & Company MN now owns 70,653 shares of the company's stock valued at $749,000 after acquiring an additional 13,196 shares in the last quarter. Numerai GP LLC increased its holdings in Neumora Therapeutics by 46.7% during the 4th quarter. Numerai GP LLC now owns 51,696 shares of the company's stock valued at $548,000 after acquiring an additional 16,457 shares in the last quarter. Finally, Rafferty Asset Management LLC purchased a new position in Neumora Therapeutics during the 4th quarter valued at about $185,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.